Resident versus Attending Surgeon Patency and Clinical Outcomes in On- versus Off- Pump Coronary Artery Bypass Surgery G Hossein Almassi, MD 1 Brendan.

Slides:



Advertisements
Similar presentations
Off pump CABG has been performed for the first time 40 years ago. Although conventional CABG is considered both safe and effective, the use of CBP.
Advertisements

MAIN-COMPARE Study Stents versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease.
V.: 9/7/2007 AC Submit1 Statistical Review of the Observational Studies of Aprotinin Safety Part I: Methods, Mangano and Karkouti Studies CRDAC and DSaRM.
THE IMPACT OF ATRIAL FIBRILLATION IN CARDIAC SURGERY Wim J De Vries. DEPARTMENT CARDIOTHORACIC SURGERY UNIVERSITY OF THE FREE STATE UNIVERSITAS HOSPITAL.
Steroids In caRdiac Surgery (SIRS) Trial
Is this the “spioenkop” for CABG?
Widimsky P, Tousek P, Rokyta R, et al. Charles University Prague, CZ PRAGUE-7 Study (Hot Lines presenter)
Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.
Impact of Preoperative Renal Dysfunction in Patients Undergoing Off- pump vs On-pump Coronary Artery Bypass.
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
CABG VS Multi Vessel PCI Hasanat Sharif MD FRCS Chief of Cardiorthoracic Surgery Aga Khan University Hospital.
CPORT- E Trial Randomized trial comparing medical, economic and quality of life outcomes of non-primary PCI at hospitals with and without on-site cardiac.
5 Years Results of Off-Pump VS On-Pump CABG 5 Years Results of Off-Pump VS On-Pump CABG Prospective Non-randomized Comparative Study Piya Cherntanomwong*,
PCI VS CABG JOURNAL REVIEW
Open Repair of Ruptured Descending Thoracic and Thoracoabdominal Aortic Aneurysms in 100 Consecutive Cases Mario F. Gaudino, Christopher Lau, Monica Munjal,
Seung-Jung Park, MD, PhD On behalf of the PRECOMBAT Investigators Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction Results of the Antithrombotics.
New guidelines for CABG
1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.
Preservation Solutions, Vein Graft Patency, and Outcomes after Coronary Bypass Surgery RE Harskamp, JH Alexander, PJ Schulte, CM Brophy, MJ Mack, ED Peterson,
Blood Pressure Lability During Cardiac Surgery Is Associated With Adverse Outcomes Solomon Aronson, Edwin G. Avery, Cornelius Dyke, Joseph Varon, Jerrold.
Author Disclosures Differences in Implantation-Related Adverse Events Between Men and Women Receiving ICD Therapy for Primary Prevention Differences in.
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.
Coronary Artery Disease in Diabetic Patients, Different from Non-diabetics?
M Ruel, V Chan, M Boodhwani, B McDonald, X Ni, G Gill, K Lam, F Rubens, P Hendry, R Masters, T Mesana Ottawa, Canada How Detrimental is Re-Exploration.
Secondary Prevention Following Coronary Artery Bypass Grafting: are we Compliant with the Guidelines? V. Joshi, B. Bridgewater University Hospital of South.
The Use of Thoracic Endovascular Stent Grafting in Acute Aortic Tragedies as Compared to Open Surgical Repair Tyler J. Wallen, BA, Wilson Y. Szeto, MD,
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies.
André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures.
André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures.
Randomized Trial of Ea rly S urgery Versus Conventional Treatment for Infective E ndocarditis (EASE) Duk-Hyun Kang, MD, PhD on behalf of The EASE Trial.
Long Term Clinical Outcomes Following Drug-Eluting and Bare Metal Stenting in Massachusetts Laura Mauri, MD, MSc; Treacy Silverstein, B.Sc.; Ann Lovett,
G. Rainey Williams Symposium September 30, 2005 CABG in the Elderly Patient: On or Off pump? A Single Center Experience R. Nathan Grantham, M.D.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
A Novel Score to Estimate the Risk of Pneumonia After Cardiac Surgery
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
Trial Design Issues Associated with Evaluation of Distal Protection Devices in Diseased Saphenous Vein Grafts Bram D. Zuckerman, MD, FACC Medical Officer,
Left Main Stem Intervention Trials & Registries Keith D. Dawkins MD FRCP FACC Southampton University Hospital UK.
1 Pre-Specified Outcomes All primary and secondary outcomes and their components were pre-specified, i.e., they appeared in the protocol, manual of operations.
Impact of Prior Myocardial Infarction Among Patients with Acute Myocardial Infarction Treated in Contemporary Practice: A Report from the ACTION Registry.
Preoperative Hemoglobin A1c and the Occurrence of Atrial Fibrillation Following On-pump Coronary Artery Bypass surgery in Type-2 Diabetic Patients Akbar.
European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.
Cardiovascular Outcomes in Hypertensives with CHD Randomized to Amlodipine versus Lisinopril in ALLHAT Frans Leenen MD, PhD, Chuke Nwachuku MA, MPH, Dr.
Lund – Malmö, SWEDEN. Is the Era of Off-pump Surgery over? ARASH MOKHTARI, MD, PHD.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Department of cardiovascular surgery Kumamoto Central Hospital Taro Nakatsu, Nobushige Tamura, Takuya Nomoto, Koji Hagio, Masanosuke Ishigami, Shouichi.
Clinical Trial Results. org Impact of Epicardial Anterior Fat Pad Retention on Postcardiothoracic Surgery Atrial Fibrillation Incidence: The AFIST-III.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
ISCHEMIC HEART DISEASE
David J McCormack MFSTEd FRCSEd (CTh) Advanced Clinical Fellow
The German Off-Pump Coronary Artery Bypass Grafting in
Single IMA {Single Arterial}
The Evidence For Conduit Choice
CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump
Saphenous Vein Grafts with Multiple Versus Single Distal Targets in Patients Undergoing Coronary Artery Bypass Surgery: One-Year Graft Failure and Five-Year.
Impact of endoscopic versus open saphenous vein harvest technique on late coronary artery bypass grafting patient outcomes in the ROOBY (Randomized On/Off.
Chronic Obstructive Pulmonary Disease Impact Upon Outcomes: The Veterans Affairs Randomized On/Off Bypass Trial  G. Hossein Almassi, MD, A. Laurie Shroyer,
A. Laurie W. Shroyer, PhD, Brack Hattler, MD, Todd H
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
A decade of change—risk profiles and outcomes for isolated coronary artery bypass grafting procedures, 1990–1999: a report from the STS National Database.
for the REGROUP Trial Investigators
Off-pump versus on-pump coronary artery bypass grafting: Insights from the Arterial Revascularization Trial  Umberto Benedetto, MD, PhD, Douglas G. Altman,
Costs Five Years After Off-Pump or On-Pump Coronary Artery Bypass Surgery  Todd H. Wagner, PhD, Brack Hattler, MD, Faisal G. Bakaeen, MD, Joseph F. Collins,
Changes in Health-Related Quality of Life in Off-Pump Versus On-Pump Cardiac Surgery: Veterans Affairs Randomized On/Off Bypass Trial  Muath Bishawi,
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Off-pump coronary artery bypass grafting decreases risk-adjusted mortality and morbidity  Joseph C Cleveland, MD, A.Laurie W Shroyer, PhD, Anita Y Chen,
A. Laurie W. Shroyer, PhD, MSHA, Jacquelyn A. Quin, MD, MPH, Todd H
Atlantic Cardiovascular Patient Outcomes Research Team
Presentation transcript:

Resident versus Attending Surgeon Patency and Clinical Outcomes in On- versus Off- Pump Coronary Artery Bypass Surgery G Hossein Almassi, MD 1 Brendan M. Carr, MS 2 Muath Bishawi, MD, MPH 3 A. Laurie Shroyer, PhD 2 Jacquelyn A. Quin, MD 4 Brack Hattler, MD 5 Todd H. Wagner, PhD 6 Joseph F. Collins, PhD 7 Pasala Ravichandran, MD 8 Joseph C. Cleveland, MD 9 Frederick L. Grover, MD 5,9 Faisal G. Bakaeen, MD 10 for the VA #517 Randomized On/Off Bypass (ROOBY) Study Group 1 Cardiothoracic Surgery, Medical College of Wisconsin and Veterans Affairs (VA) Medical Center, Milwaukee, WI; 2 Surgery, Northport VA Medical Center and Stony Brook Medicine School of Medicine, Stony Brook, NY; 3 Surgery, Duke University, Durham, NC; 4 Cardiac Surgery, VA Boston Healthcare System, West Roxbury, MA; 5 Cardiology, VA Eastern Colorado Health Care System, Denver, CO; 6 VA Palo Alto Health Economics Resource Center, Menlo Park, CA and Department of Health Research and Policy, Stanford University, Stanford, CA; 7 Cooperative Studies Program Coordinating Center and VA Medical Center, Perry Point, Maryland; 8 Surgery, Oregon Health and Sciences University and Portland VA Medical Center, Portland, OR; 9 Surgery, University of Colorado School of Medicine at the Anschutz Medical Campus, Aurora, CO; 10 Cardiothoracic Surgery, Baylor College of Medicine and Houston VA Medical Center, Houston, TX

Presenter Disclosure No disclosure to report

Funding Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development and the Department of Veterans Affairs Central Office, Office of Patient Care Services. Offices of Research and Development at the Zablocki VA Medical Center, Northport VA Medical Center, and the VA Eastern Colorado Healthcare System.

Background  Residents must be trained to perform cardiac surgical procedures  Balance between education and what is best for the patient  Prior studies have shown no impact on CABG clinical outcomes  Little information about effect on graft patency

Background  Bakaeen et al., 2012 – residents and attendings had similar outcomes and 1-year patency  Bakaeen et al., 2009 – residents had longer operative times, perfusion and cross-clamp times, but similar outcomes  Guo et al., 2008 – residents /fellows vs. consultants had similar operative morbidity and mortality in on- pump CABG

Background  Haan et al., 2007 – hospitals with residency programs have longer perfusion times but similar outcomes  Asimakopoulos et al., 2006 – residents had similar operative morbidity and mortality in off-pump CABG  Ascione et al., 2004 – residents had similar morbidity and mortality in high-risk off-pump CABG patients

Research Questions  Do different clinical outcomes result when residents vs. attendings perform the majority of distal coronary anastomoses?  Do grafts performed during CABG by residents vs. attendings have different rates of patency at 1 year postop?  Are these results different for on-pump vs. off-pump CABG?

ROOBY Trial  VA Cooperative Study (18 centers)  February 2002 – May 2008  Prospective, randomized, single-blinded  Comparison of CABG with and without CPB  ONCAB (n = 1,099)  OPCAB (n = 1,104)  Total (n = 2,203)

Study Population  All patients = 1,272  16 centers with cardiac surgery residents  Data on resident anastomoses captured beginning July 2003  OPCAB = 639 Patients  Resident as primary surgeon: 431 (67.4%)  ONCAB = 633 Patients  Resident as primary surgeon: 493 (77.9%)

Definition  Primary surgeon:  The individual (resident or attending) who performed ≥ 50% of the distal anastomoses in a given patient

Clinical Outcomes  Short-term (30-day) composite endpoint:  Death  Reoperation  New mechanical support  Cardiac arrest  Coma  Stroke  Renal failure requiring dialysis  1-year composite endpoint:  Death from any cause within 1 year after surgery  Nonfatal myocardial infarction between 30 days and 1 year  Any revascularization procedure between 30 days and 1 year

Graft Patency  Coronary angiography at 1 year postop  FitzGibbon classification  A = An excellent/unimpaired graft  B = An impaired graft with a stenosis >50% reducing the caliber of the graft to <50% of the target artery diameter  O = A completely occluded graft

Statistical Methods  Discrete variables: Chi-square or Fisher Exact tests  Continuous variables: Student T-tests  Multivariate Regression  Significance at p < 0.01 for all ROOBY sub-studies

Results

Baseline patient characteristics Patient risk profile On-pump N=633 Off-pump N=639 Resident n/N (%) Attending n/N (%) p-value Resident n/N (%) Attending n/N (%) p-value COPD119/493 (24.1)20/140 (14.3) /431 (20.6)44/208 (21.2)0.88 Creatinine > 1.5 mg/dl30/493 (6.1)14/140 (10.0)0.1138/431 (8.8)17/208 (8.2)0.79 Cerebrovascular accident31/493 (6.3)13/140 (9.3)0.2226/431 (6.0)14/208 (6.7)0.73 Peripheral artery disease61/493 (12.4)18/140 (12.9)0.8865/431 (15.1)40/208 (19.2)0.18 Diabetes233/493 (47.3)63/140 (45.0) /431 (46.9)82/208 (39.4)0.08 Hypertension424/493 (86.0)128/140 (91.4) /431 (86.8)180/208 (86.5)0.93 Atrial fibrillation10/493 (2.0)2/140 (1.4)0.6514/429 (3.3)11/208 (5.3)0.22 LVEF by category < 35% ≥ 35% 23/485 (4.7) 462/485 (95.3) 5/132 (3.8) 127/132 (96.2) /419 (4.5) 400/419 (95.5) 17/201 (8.5) 184/201 (91.5) 0.05 Prior MI142/490 (29.0)39/138 (28.3) /427 (27.2)63/208 (30.3)0.41 β-Blocker Use302/493 (61.3)83/140 (59.3) /431 (63.8)127/208 (61.1)0.50 Aspirin411/493 (83.4)119/140 (85.0) /431 (85.8)168/208 (80.8)0.10 Urgent case60/493 (12.2)16/140 (11.4)0.8162/431 (14.4)27/208 (13.0)0.63

*NOTE: p-value is for the comparison between treatment groups Coronary anatomy On-pump N=633 Off-pump N=639 Resident n/N (%) Attending n/N (%) p-value Resident n/N (%) Attending n/N (%) p-value Territories with disease /493 (6.9) 133/493 (27.0) 322/493 (65.3) 9/140 (6.4) 31/140 (22.1) 100/140 (71.4) /431 (7.9) 132/431 (30.6) 263/431 (61.0) 11/207 (5.3) 61/207 (29.5) 132/207 (63.8) 0.35 Distals performed by Resident only Attending only Both 303/633 (47.9) 121/633 (19.1) 209/633 (33.0) 269/639 (42.1) 168/639 (26.3) 202/639 (31.6) 0.008* Coronary territories and anastomoses per primary surgeon

On-pump n/N (%) OR mean ± SD Off-pump n/N (%) OR mean ± SD ResidentAttendingp-valueResidentAttendingp-value LAD anastomoses Quality of target Good/Moderate Poor 450/482 (93.4) 32/482 (6.6) 118/136 (86.8) 18/136 (13.2) /443 (93.5) 29/443 (6.5) 159/179 (88.8) 20/179 (11.2) 0.05 Diagonal anastomoses Quality of target Good/Moderate Poor 164/176 (93.2) 12/176 (6.8) 48/51 (94.1) 3/51 (5.9) /129 (88.4) 15/129 (11.6) 62/69 (89.9) 7/69 (10.1) 0.75 Circumflex (AV) / OM anastomoses Quality of target Good/Moderate Poor 304/331 (91.8) 27/331 (8.2) 130/145 (89.7) 15/145 (10.3) /227 (91.2) 20/227 (8.8) 196/211 (92.9) 15/211 (7.1) 0.51 Ramus anastomoses Quality of target Good/Moderate Poor 40/45 (88.9) 5/45 (11.1) 15/18 (83.3) 3/18 (16.7) /41 (97.6) 1/41 (2.4) 28/30 (93.3) 2/30 (6.7) 0.38 Right main coronary anastomoses Quality of target Good/Moderate Poor 43/47 (91.5) 4/47 (8.5) 36/40 (90.0) 4/40 (10.0) /59 (94.9) 3/59 (5.1) 46/52 (88.5) 6/52 (11.5) 0.21 PDA anastomoses Quality of target Good/Moderate Poor 134/156 (85.9) 22/156 (14.1) 126/151 (83.4) 25/151 (16.6) /127 (89.0) 14/127 (11.0) 130/142 (91.5) 12/142 (8.5) 0.48 Posterolateral anastomoses Quality of target Good/Moderate Poor 21/23 (91.3) 2/23 (8.7) 14/18 (77.8) 4/18 (22.2) /14 (100.0) 0/14 (0.0) 17/18 (94.4) 1/18 (5.6) 0.37 Comparison of target vessels quality based on who actually performed the anastomoses

Operative variables by primary surgeon Patients operative profile On-pump N=633 Off-pump N=639 Resident n/N (%) Attending n/N (%) p-value Resident n/N (%) Attending n/N (%) p-value Units of packed RBC 1.0 ± 1.6 (n=493) 0.9 ± 1.6 (n=140) ± 1.5 (n=430) 1.0 ± 1.6 (n=208) 0.65 Units of fresh frozen plasma 0.4 ± 1.1 (n=493) 0.5 ± 1.4 (n=140) ± 1.3 (n=430) 0.5 ± 1.3 (n=208) 0.73 Units of platelets 0.3 ± 1.5 (n=493) 0.1 ± 0.6 (n=140) ± 1.7 (n=430) 0.4 ± 1.5 (n=208) 0.96 Take down and redo of distal 14/493 (2.8)6/140 (4.3)0.3917/431 (3.9)5/208 (2.4)0.32

Short-term Clinical Outcomes * Short-term composite endpoint included death, reoperation, new mechanical support, cardiac arrest, coma, stroke, or renal failure requiring dialysis before discharge or within 30 days after surgery On-pump n/N (%) OR mean ± SD Off-pump n/N (%) OR mean ± SD ResidentAttending p-valueResidentAttendingp-value Short-term composite*24/493 (4.9)10/140 (7.1)0.2927/431 (6.3)10/208 (4.8)0.46 Reoperation for bleeding9/493 (1.8)4/140 (2.9)0.4514/431 (3.2)4/208 (1.9)0.34 Stroke3/493 (0.6)2/140 (1.4)0.333/431 (0.7)2/208 (1.0)0.72 Renal failure requiring dialysis 2/493 (0.4)0/140 (0.0)0.453/431 (0.7)2/208 (1.0)0.72 Prolonged vent >48hrs15/493 (3.0)6/140 (4.3)0.4721/431 (4.9)9/208 (4.3)0.76 Re-intubation13/493 (2.6)5/140 (3.6)0.5616/429 (3.7)5/208 (2.4)0.38 MI18/493 (3.7)4/140 (2.9)0.6525/431 (5.8)12/208 (5.8)0.99 New mechanical sup.5/493 (1.0)1/140 (0.7)0.755/431 (1.2)4/208 (1.9)0.44 Mediastinitis4/493 (0.8)4/140 (2.9)0.063/431 (0.7)5/208 (2.4)0.07 Operative Death3/493 (0.6)2/140 (1.4)0.335/431 (1.2)1/208 (0.5)0.40 Hospital length of stay (days) 7.6 ± 5.3 (n=486) 8.1 ± 6.8 (n=139) ± 4.4 (n=425) 7.9 ± 5.6 (n=203) 0.53

1-Year Clinical Outcomes On-pump n/N (%) OR mean ± SD (n) Off-pump n/N (%) OR mean ± SD (n) ResidentAttendingp-valueResidentAttendingp-value 1-year composite*32/493 (6.5)8/140 (5.7)0.7444/431 (10.2)19/208 (9.1)0.67 All-cause death12/493 (2.4)4/140 (2.9)0.7817/431 (3.9)5/208 (2.4)0.32 Repeat revascularization† 16/493 (3.2)4/140 (2.9)0.8225/431 (5.8)11/208 (5.3)0.79 Non-fatal MI†8/493 (1.6)2/140 (1.4)0.875/431 (1.2)4/208 (1.9)0.44 * 1-year composite endpoint included death from any cause within 1 year after surgery, nonfatal myocardial infarction between 30 days and 1 year, and any revascularization procedure between 30 days and 1 year † These two late adverse outcomes were evaluated from the time of 30-days post-surgery up until 1-year follow-up

On-pumpOff-pump Resident n/N (%) Attending n/N (%) p-valueResident n/N (%) Attending n/N (%) p-value Overall A B O 590/711 (83.0) 23/711 (3.2) 98/711 (13.8) 262/318 (82.4) 8/318 (2.5) 48/318 (15.1) /636 (77.2) 27/636 (4.2) 118/636 (18.6) 328/428 (76.6) 20/428 (4.7) 80/428 (18.7) 0.94 SVG A B O 314/414 (75.8) 15/414 (3.6) 85/414 (20.5) 178/228 (78.1) 8/228 (3.5) 42/228 (18.4) /369 (70.5) 12/369 (3.3) 97/369 (26.3) 213/294 (72.4) 13/294 (4.4) 68/294 (23.1) 0.51 LIMA A B O 253/268 (94.4) 6/268 (2.2) 9/268 (3.4) 71/74 (95.9) 0/74 (0.0) 3/74 (4.1) /247 (88.7) 14/247 (5.7) 99/112 (88.4) 5/112 (4.5) 8/112 (7.1) Year FitzGibbon Patency A = An excellent/unimpaired graft B = An impaired graft with a stenosis >50% reducing the caliber of the graft to <50% of the target artery diameter O = A completely occluded graft SVG = Saphenous vein graft LIMA = Left internal mammary artery

Limitations  Attendings could have assisted residents in ways not documented  Predominantly male veteran population  Subgroup analysis  Resident anastomosis data not captured during first year of ROOBY trial  Follow-up limited to 1 year

Conclusions  For ROOBY Trial patients:  No difference in perioperative outcomes  No difference in 1-year outcomes  No difference in 1-year graft patency

Conclusion Residents can and should be trained in advanced surgical techniques with no negative impact on surgical outcomes.

Thank You